Shreya Life Sciences has launched recombinant human insulin under the brand name Recosulin. The technology has been licensed from Biotechnology General Corporation (BTGC) (now known as Savient Inc.), USA.
The company has introduced full range of insulin to suit individual patient requirements in both 40 IU/ml & 100 IU/ml, namely Recosulin M30 - Pre Mixed 30/70; Recosulin N - NPH and Recosulin R - Regular.
Recosulin has been developed using Advanced Technology in Second Generation rDNA Human Insulin. Previous technology for human insulin uses Methionine as a linker molecule that requires 24 stage unit operations involving treatment with harsh chemicals like Cynogen Bromide.
However, advanced technology from BTGC does not require Methionine and uses Lysine and Arginine instead. With this technology, the manufacturer of Recosulin requires only 19 stage unit operations without any involvement of harsh chemicals. This technology has been patented by Shreya's collaborator.
Announcing the launch of Recosulin and Recojet, Sujit Kumar Singh, chairman, Shreya Group said, "Shreya has entered the area of diabetes care as a serious long-term player and introduced oral antidiabetics, diabetes specific nutrients and recombinant human insulin. We are committed to bringing world-class diabetes therapy to India and are making major investments in manufacturing, R&D and marketing to make diabetes therapy affordable to a larger number of patients."
Initially, Shreya will launch Recosulin by importing finished product from Bioton, Poland (manufactured using BTGC technology).
In the second phase, crystals will be imported and formulated at Shreya's manufacturing facility at Aurangabad.
Along with the launch of Recosulin, Shreya is also launching Recojet, which is considered to be the country's first needle-free painless insulin delivery device.
Recojet has been brought to India by Shreya through an exclusive arrangement with Antares Pharma, a US-based global leader in developing innovative technologies for delivering drugs across the skin, through its partner, Scigen of Singapore.